Diagnostic Pathology: Molecular Oncology

Covering all aspects of molecular pathology as it relates to the transformation and pathogenesis of cancer, this award-winning volume in the Diagnostic Pathology?series is an expert resource for pathologists at all levels of experience and training, both as a quick reference and as an efficient review to improve knowledge and skills. This easily accessible, point-of-care reference features templated, bulleted content that is generously illustrated with charts, graphs, tables, and color photomicrographs of histology with special stains. It offers a practical, clinical approach to examining how molecular mutations affect common medical diseases and identifies the relevant and appropriate molecular tests to perform for a complete work-up in the era of molecular-targeted therapies. Provides updated information on molecular mutations in different tumors, including solid tumors and hematopoietic neoplasms, and new targeted therapies geared toward these molecular alterations Discusses now widely used immunotherapy treatments, including how immunotherapy has revolutionized the treatment of many neoplasms such as breast and lung carcinomas and lymphoma Features more than 2,000 annotated images throughout, including H&E stains, immunostains, and FISH images Covers timely topics such as: Recent advances in cancer immunotherapy, specifically in the molecular basis of immunotherapy Newly discovered targeted therapies, including multiple lung carcinoma therapies now considered for patients based on existing mutations to specific genes (KRAS, ALK, BRAF, and ROS) The need for integration of myeloid and lymphoid gene panels due to increased knowledge from next generation sequencing studies of new mutations and the resulting newly developed molecular targets Increased usage of next generation sequencing techniques Changes to hematopoietic tumor details based on revised WHO guidelines Recipient of a 2016 BMA Award: Highly Commended, Pathology (previous edition) Enhanced eBook version included with purchase, which allows you to access all of the text, figures, and references from the book on a variety of devices.

·  SECTION 1: INTRODUCTION

·  Chapter 1: Structure of Chromosomes and Nucleic Acids

·  Chapter 2: DNA Replication, Transcription, and Translation

·  Chapter 3: Gene Mutations

·  SECTION 2: COMMON TECHNIQUES FOR ANALYSIS OF ALTERATIONS IN CHROMOSOMES AND DNA

·  Chapter 4: Cytogenetics and FISH

·  Chapter 6: Amplification Methods

·  Chapter 7: DNA High-Resolution Melting Curve Analysis

·  Chapter 8: Sequencing Technologies

·  Chapter 9: High-Throughput Methods in Molecular Pathology

·  Chapter 10: DNA Methylation Analysis

·  SECTION 3: MOLECULAR GENETIC TESTS IN HEMATOPOIETIC TUMORS

·  Chapter 11: BCR-ABL1 Fusion Gene

·  Chapter 12: PML-RARA Fusion Gene

·  Chapter 13: Reverse Transcription PCR for Other Myeloid Leukemia Transcripts

·  Chapter 14: FLT3, NPM1, and CEBPA Mutations

·  Chapter 15: JAK2 Mutations and Rearrangements

·  Chapter 16: MPL Mutations

·  Chapter 17: Calreticulin (CALR) Mutations

·  Chapter 18: CSF3R Mutations

·  Chapter 19: SETBP1 Mutations

·  Chapter 20: KIT Mutations

·  Chapter 21: IDH1 and IDH2 Mutations

·  Chapter 22: Other Mutations and Gene Panel Testing in Myeloid Neoplasms

·  Chapter 23: Immunoglobulin Heavy (IGH) Chain Gene Rearrangements

·  Chapter 24: T-Cell Receptor Gamma (TRG) and Delta (TRD) Chain Rearrangements

·  Chapter 25: T-Cell Receptor Beta (TRB) Chain Gene Rearrangements

·  Chapter 26: Southern Blot Analysis of Antigen Receptor Genes

·  Chapter 27: EBV-Associated Human Neoplasms

·  Chapter 28: MYD88 Mutation

·  Chapter 29: NOTCH1 Mutation

·  Chapter 30: EZH2 Mutation

·  SECTION 4: MOLECULAR GENETIC TESTS IN SOLID TUMORS, BONE AND SOFT TISSUE TUMORS, AND CNS TUMORS

·  Chapter 31: ALK Gene Rearrangements and Mutations

·  Chapter 32: ROS1 Rearrangements

·  Chapter 33: RET Rearrangements

·  Chapter 34: FISH for MET Amplifications

·  Chapter 35: FISH for ERBB2 (HER2) Gene Amplifications

·  Chapter 36: KRAS Mutations

·  Chapter 37: BRAF Mutations

·  Chapter 38: EGFR Mutations

·  Chapter 39: Targeted Hotspot Gene Panel Using Massively Parallel Sequencing (Next-Generation Sequencing)

·  Chapter 40: Targeted Hotspot Gene Panel Table

·  Chapter 41: MGMT Promoter Gene Methylation Assay

·  SECTION 5: MOLECULAR PATHOLOGY OF MYELOID NEOPLASMS

·  Chapter 42: Molecular Work-Up of Myeloid Neoplasms

·  Chapter 43: Chronic Myeloid Leukemia, BCR-ABL1 Positive

·  Chapter 44: Chronic Neutrophilic Leukemia

·  Chapter 45: Polycythemia Vera

·  Chapter 46: Primary Myelofibrosis

·  Chapter 47: Essential Thrombocythemia

·  Chapter 48: Chronic Eosinophilic Leukemia, NOS

·  Chapter 49: Myeloproliferative Neoplasms, Unclassifiable

·  Chapter 50: Mastocytosis

·  Chapter 51: Myeloid/Lymphoid Neoplasms With Eosinophilia and Gene Rearrangement

·  Chapter 52: Overview and Classification of Myelodysplastic Syndrome

·  Chapter 53: Myelodysplastic Syndromes With Single-Lineage Dysplasia

·  Chapter 54: Myelodysplastic Syndrome With Ring Sideroblasts

·  Chapter 55: Myelodysplastic Syndrome With Multilineage Dysplasia

·  Chapter 56: Myelodysplastic Syndrome With Isolated del(5q)

·  Chapter 57: Myelodysplastic Syndrome, Unclassifiable

·  Chapter 58: Childhood Myelodysplastic Syndrome and Refractory Cytopenia of Childhood

·  Chapter 59: Overview of Myelodysplastic/Myeloproliferative Neoplasms

·  Chapter 60: Chronic Myelomonocytic Leukemia

·  Chapter 61: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

·  Chapter 62: Juvenile Myelomonocytic Leukemia

·  Chapter 63: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

·  Chapter 64: Overview of Acute Myeloid Leukemia

·  Chapter 65: Acute Myeloid Leukemia With t(8;21); RUNX1-RUNX1T1

·  Chapter 66: Acute Myeloid Leukemia With inv(16) or t(16;16); CBFB-MYH11

·  Chapter 67: Acute Promyelocytic Leukemia With t(15;17); PML-RARA

·  Chapter 68: Acute Myeloid Leukemia With t(9;11); MLLT3-KMT2A

·  Chapter 69: Acute Myeloid Leukemia With t(6:9); DEK-NUP214

·  Chapter 70: Acute Myeloid Leukemia With inv(3) or t(3;3); GATA2, MECOM

·  Chapter 71: Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22); RBM15-MRTFA

·  Chapter 72: Acute Myeloid Leukemia With Myelodysplasia-Related Changes

·  Chapter 73: Acute Myeloid Leukemia, NOS

·  Chapter 74: Therapy-Related Myeloid Neoplasms

·  Chapter 75: Myeloid Sarcoma

·  Chapter 76: Myeloid Proliferations Associated With Down Syndrome

·  Chapter 77: Blastic Plasmacytoid Dendritic Cell Neoplasm

·  Chapter 78: Overview of Lymphoid Neoplasms

·  Chapter 79: Molecular Work-Up of Lymphoid Neoplasms

·  Chapter 80: Lymphoma-Associated Chromosomal Translocations

·  Chapter 81: B-Lymphoblastic Leukemia/Lymphoma With Recurrent Genetic

 

·  Chapter 82: B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like (Ph-Like ALL)

·  TERMINOLOGY

·  EPIDEMIOLOGY

·  ETIOLOGY/PATHOGENESIS

·  CLINICAL IMPLICATIONS

·  Chapter 83: T-Lymphoblastic Leukemia/Lymphoma

·  Chapter 84: Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

·  Chapter 85: B-Cell Prolymphocytic Leukemia

·  Chapter 86: Splenic Marginal Zone Lymphoma

·  Chapter 87: Hairy Cell Leukemia

·  Chapter 88: Splenic B-Cell Lymphoma/Leukemia, Unclassifiable

·  Chapter 89: Lymphoplasmacytic Lymphoma

·  Chapter 90: Monoclonal Gammopathy of Undetermined Significance

·  Chapter 91: Plasma Cell Myeloma

·  Chapter 92: Follicular Lymphoma

·  Chapter 93: Mantle Cell Lymphoma

·  Chapter 94: Diffuse Large B-Cell Lymphoma

·  Chapter 95: Burkitt Lymphoma

·  Chapter 96: T-Cell Prolymphocytic Leukemia

·  Chapter 97: Chronic Lymphoproliferative Disorder of NK Cells

·  Chapter 98: Aggressive NK-Cell Leukemia

·  Chapter 99: Extranodal NK-/T-Cell Lymphoma, Nasal Type

·  Chapter 100: Adult T-Cell Leukemia/Lymphoma

·  Chapter 101: Intestinal T-Cell Lymphoma

·  Chapter 102: Hepatosplenic T-Cell Lymphoma

·  Chapter 103: Subcutaneous Panniculitis-Like T-Cell Lymphoma

·  Chapter 104: Mycosis Fungoides/Sézary Syndrome

·  Chapter 105: Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders

·  Chapter 106: Peripheral T-Cell Lymphoma, NOS

·  Chapter 107: Angioimmunoblastic T-Cell Lymphoma

·  Chapter 108: Anaplastic Large Cell Lymphoma, ALK Negative

·  Chapter 109: Anaplastic Large Cell Lymphoma, ALK Positive

·  SECTION 7: MOLECULAR PATHOLOGY OF DENDRITIC CELL AND HISTIOCYTIC NEOPLASMS

·  Chapter 110: Histiocytic Sarcoma

·  Chapter 111: Tumors Derived From Langerhans Cells

·  Chapter 112: Interdigitating Dendritic Cell Tumor

·  Chapter 113: Follicular Dendritic Cell Neoplasm

·  SECTION 8: MOLECULAR PATHOLOGY OF SOLID TUMORS

·  HEAD AND NECK, INCLUDING SINONASAL TUMORS AND SALIVARY GLANDS

·  Chapter 114: HPV-Associated Head and Neck Carcinomas

·  Chapter 115: Head and Neck Mucosal Squamous Cell Carcinoma, Non-HPV Related

·  Chapter 116: Important Alterations in Non-HPV-Related Head and Neck Squamous Cell Carcinoma

·  Chapter 117: Translocation-Specific Salivary Gland Tumors 1

·  Chapter 118: Translocation-Specific Salivary Gland Tumors 2

·  Chapter 119: Nasopharyngeal EBV-Related Squamous Cell Carcinoma

·  Chapter 120: Other Head and Neck Tumors

·  Chapter 121: Papillary Thyroid Carcinoma

·  Chapter 122: Follicular Thyroid Carcinoma

·  Chapter 123: Poorly Differentiated Thyroid Carcinoma

·  Chapter 124: Undifferentiated Thyroid Carcinoma

·  Chapter 125: Medullary Thyroid Carcinoma

·  Chapter 126: Adenocarcinoma, Lung

·  Chapter 127: Squamous Cell Carcinoma, Lung

·  Chapter 128: Small Cell Neuroendocrine Carcinoma

·  Chapter 129: Mesothelioma

·  Chapter 130: Gastric Adenocarcinoma

·  Chapter 131: Colorectal Adenocarcinoma and Precancerous Lesions

·  Chapter 132: Gastrointestinal Stromal Tumor

·  Chapter 133: HNF1α-Inactivated Hepatocellular Adenoma

·  Chapter 134: β-Catenin-Activated Hepatocellular Adenoma

·  Chapter 135: Inflammatory Hepatocellular Adenoma

·  Chapter 136: Hepatocellular Carcinoma

·  Chapter 137: Pancreatic Ductal Adenocarcinoma

·  Chapter 138: Pancreatic Mucinous Cystic Neoplasm

·  Chapter 139: Pancreatic Intraductal Papillary Mucinous Neoplasm

·  Chapter 140: Cholangiocarcinoma

·  Chapter 141: Testicular Germ Cell Tumors

·  Chapter 142: Clear Cell Renal Cell Carcinoma

·  Chapter 143: Chromophobe Renal Cell Carcinoma

·  Chapter 144: Papillary Renal Cell Carcinoma

·  Chapter 145: MiT Family Translocation Renal Cell Carcinomas

·  Chapter 146: Wilms Tumor

·  Chapter 147: Clear Cell Sarcoma of Kidney

·  Chapter 148: Oncocytoma

·  Chapter 149: Rhabdoid Tumor of Kidney

·  Chapter 150: Urothelial Carcinoma

·  Chapter 151: Pheochromocytoma/Paraganglioma

·  Chapter 152: Adrenal Cortical Carcinoma

·  Chapter 153: Neuroblastoma

·  Chapter 154: Adrenal Cortical Adenoma

·  Chapter 155: Prostatic Adenocarcinoma, Acinar Type and High-Grade Prostatic Intraepithelial Neoplasia

·  Chapter 156: ADH and DCIS (Dysplastic, Premalignant)

·  Chapter 157: Ductal Carcinomas

·  Chapter 158: Lobular Carcinoma

·  Chapter 159: Carcinoma With Medullary Features, Breast

·  Chapter 160: Metaplastic Breast Carcinoma

·  Chapter 161: Phyllodes Tumors

·  Chapter 162: Basal-Like and Triple-Negative Carcinomas

·  Chapter 163: Preneoplastic Conditions, Cervix/Vulva/Vagina

·  Chapter 164: Squamous Cell Carcinoma, Cervix/Vulva/Vagina

·  Chapter 165: Adenocarcinoma, Cervix/Vulva/Vagina

·  Chapter 166: Endometrial Intraepithelial Neoplasia

·  Chapter 167: Uterine Endometrioid Carcinoma

·  Chapter 168: Uterine Serous Carcinoma

·  Chapter 169: Clear Cell Carcinoma, Uterus

 

·  Chapter 170: Uterine Sarcomas

·  Chapter 171: Serous Tumors of Ovary and Fallopian Tube

·  Chapter 172: Other Surface Epithelial Tumors of Ovary

·  Chapter 173: Sex Cord-Stromal Tumors of Ovary

·  Chapter 174: Germ Cell Tumor, Ovary

·  Chapter 175: Preneoplastic Conditions, Skin

·  Chapter 176: Melanoma

·  Chapter 177: Squamous Cell Carcinoma, Skin

·  Chapter 178: Basal Cell Carcinoma, Skin

·  Chapter 179: Other Skin Conditions

·  Chapter 180: Overview of Molecular Pathology of Bone and Soft Tissue Tumors

·  Chapter 181: Osteosarcomas

·  Chapter 182: Ewing Sarcoma

·  Chapter 183: Other Small Round Blue Cell Sarcomas

·  Chapter 184: Giant Cell Tumor of Bone

·  Chapter 185: Intermediate and Malignant Cartilaginous Tumors of Bone

·  Chapter 186: Intermediate and Malignant Myofibroblastic/Fibroblastic Tumors

·  Chapter 187: Liposarcomas

·  Chapter 188: Muscle Sarcomas

·  Chapter 189: Intermediate and Malignant Vascular Tumors

·  Chapter 190: Malignant Peripheral Nerve Sheath Tumor

·  Chapter 191: Representative Genetic Findings in Bone and Soft Tissue Tumors

·  Chapter 192: Rare Sarcomas of Uncertain Differentiation With Specific Molecular Alterations

·  Chapter 193: High-Grade Astrocytoma

·  Chapter 194: Low-Grade Astrocytoma

·  Chapter 195: Pilocytic Astrocytoma

·  Chapter 196: Oligodendroglioma

·  Chapter 197: Ependymoma

·  Chapter 198: Medulloblastoma

·  Chapter 199: Choroid Plexus Tumors

·  Chapter 200: Meningioma

·  Chapter 201: Retinoblastoma

·  SECTION 9: QUALITY ASSURANCE AND REGULATORY ISSUES

·  Chapter 202: Federal Agencies and Regulation of Laboratories

·  Chapter 203: FDA Regulations

·  Chapter 204: Proficiency Testing and Accreditation

 

 

An aparitie	8 Oct 2019
Autor	Mohammad A. Vasef MD , Aaron Auerbach MD MPH
Dimensiuni	22.2 x 4.4 x 27.9 cm
Editura	Elsevier
Format	Hardcover
ISBN	9780323611442
Limba	Engleza
Nr pag	1016